An appeal has been made for vets to drive research that may increase the survival rate of dogs with immune-mediated haemolytic anaemia (IMHA).

IMHA study dog
IMHA is a common haematological canine disease that destroys patients’ red blood cells by their own immune system.

IMHA is a common haematological canine disease that destroys patients’ red blood cells by their own immune system, leading to the development of anaemia. Treatment involves immunosuppression of patients.

Until immunosuppression is effective, patients can be supported with a range of therapies, including blood transfusion.

High mortality

Despite the increasing availability of transfusions, mortality for patients with IMHA remains high – reported to be between 30% and 70%. The AHT is working with other specialist centres on a new approach to the condition.

Despite the wide array of immunosuppressive treatment protocols described for the treatment of IMHA, best practice remains highly controversial.

Corticosteroids are typically accepted as a mainstay of therapy, although evidence supporting this is lacking. IV immunoglobulins are thought to have many potential immunomodulatory effects, and these include inhibition of phagocytosis and inhibition of complement activation, meaning this may be unique in its ability to accelerate IMHA remission.

The AHT received a donation of Pentaglobin, an IV immunoglobulin, from the family of a human patient hoping to put surplus stock to good use.

Pentaglobin is not a licensed or recognised veterinary treatment, but human immunoglobulins have been used in veterinary patients, with some studies showing promising results. The VMD has approved use of Pentaglobin for this study.

Research participation

Together with Dick White Referrals, the University of Cambridge Queen’s Veterinary School Hospital and Davies Veterinary Specialists, the AHT aims to determine if administration of Pentaglobin at the time of initial diagnosis of IMHA in dogs is beneficial for their outcome.

It is hoped Pentaglobin will improve survival in dogs when given in addition to conventional therapies. As part of this multi-centre study, the collaborators need to test the drug’s effect on dogs diagnosed with IMHA admitted to participating hospitals.

They are asking for any cases diagnosed to be highlighted to the most convenient study centre to participate in the research. Participation will be voluntary, with informed owner consent at the time of hospital admission, or once sufficient diagnostics are performed to meet the inclusion criteria.

For more information and what to do if you see a case suffering from IMHA, visit the AHT website or contact one of the following people:

View your activity >

Leave a Reply

Be the First to Comment!

Notify of


related content

The VMD has issued a product defect recall alert for specified batches of a pour-on cattle ectoparasiticide due to reported leakage problems.

2 mins

Tickets remain for this year’s Cx Congress at the East Midlands Conference Centre on 17 June.

2 mins

A study of dog DNA has revealed a genetic mutation linked to flat face shapes, such as those seen in pugs and bulldogs.

2 mins

Nick Marsh welcomes the trend towards greater specialism in veterinary medicine, but champions the importance (and hard work) of "jack of all trades" general practitioners.

14 mins

Veterinary experts, doctors and scientists have come together in a one health coalition to drive the acquisition of knowledge into one of the UK’s most baffling and lethal canine diseases.

4 mins

Heart rate variability is an established risk factor for mortality in both healthy dogs and animals with heart failure, according to a study.

2 mins